In vitro epithelial models comprising lamina propria-derived cells

Patent metadata

Field	Value
Publication number	US-10828638-B2
Application number	US-201715819435-A
Country	US
Kind code	B2
Filing date	Nov 21, 2017
Priority date	Dec 2, 2016
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory tissue, e.g., autoimmune disorders involving epithelia and diseases involving epithelial layers. These multicellular, layered microfluidic “organ-on-chip”, e.g. “epithelia-on-chip” further allow for comparisons between types of epithelia tissues, e.g., lung (Lung-On-Chip), bronchial (Airway-On-Chip), skin (Skin-On-Chip), cervix (Cervix-On-Chip), blood brain barrier (BBB-On-Chip), etc., in additional to neurovascular tissue, (Brain-On-Chip), and between different disease states of tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic “organ-on-chips” allow identification of cells and cellular derived factors driving disease states in addition to drug testing for reducing inflammation effecting epithelial regions.

First claim

What is claimed is:

1. A method comprising:
(a) providing a first microfluidic device comprising
i) a first fluidic channel in fluidic communication with a second microfluidic channel, with a semi-permeable membrane disposed between said first and second microfluidic channels,
ii) first cells comprising at least one parenchymal cell type, said first cells are positioned in said first microfluidic channel or said second microfluidic channel, and
iii) second cells comprising at least one stromal cell type, said second cells are positioned in said first microfluidic channel or said second microfluidic channel, wherein said stromal cell type is a lamina propria-derived cell; and

(b) perfusing said first microfluidic device with fluid.

2. The method of claim 1 , wherein said parenchymal cell type is selected from the group consisting of epithelial cells of the lung, epithelial cells of the skin and epithelial cells of the urogenital tract.

3. The method of claim 2 , wherein said epithelial cells of the lung are selected from the group consisting of alveolar epithelial cells and airway epithelial cells.

4. The method of claim 1 , wherein at least one of said first cells and second cells comprise cells derived from a tumor.

5. The method of claim 1 , wherein at least one of said first cells and second cells comprise cells derived from a region in or around a tumor.

6. The method of claim 1 , wherein at least one of said first cells and second cells comprise cells from a region of inflammation.

7. The method of claim 1 , wherein at least a portion of said second cells are disposed in contact with said semi-permeable membrane.

8. The method of claim 1 , wherein the device further comprises a gel.

9. The method of claim 8 , wherein at least a portion of said second cells are disposed within said gel.

10. The method of claim 1 , wherein said device further comprises a removable top.

11. The method of claim 10 , wherein said method further comprises c) removing said removable top.

12. The method of claim 1 , wherein said device further comprises an open region in contact with at least one of said first fluidic channel, said semi-permeable membrane, said first cells, or said second cells.

13. The method of claim 1 , further comprising c) contacting said first cells, said second cells or both with a first agent.

14. The method of claim 13 , further comprising d) detecting at least one response to said first agent.

15. The method of claim 14 , wherein the said at least one response comprises modulation of the inflammation reaction.

16. The method of claim 14 , wherein the said at least one response comprises modulation of cytokine profile.

17. The method of claim 14 , wherein the said at least one response comprises modulation of gene expression.

18. The method of claim 14 , wherein the said at least one response comprises modulation of cell or tissue morphology.

19. The method of claim 13 , wherein said first agent causes an inflammatory reaction.

20. The method of claim 19 , wherein the method further comprises d) contacting said first cells, said second cells or both with a second agent.

21. The method of claim 20 , wherein the method further comprises e) detecting inhibition of said inflammatory reaction by said second agent.

22. The method of claim 21 , wherein the method further comprises f) comparing the degree of inhibition by said second agent with said second cells of a first patient with the degree of inhibition by said second agent with second cells of a second patient.

23. The method of claim 21 , wherein the method further comprises f) comparing the degree of inhibition by said second agent with said second cells of a first organ with the degree of inhibition by said second agent with second cells of a second organ.

24. The method of claim 21 , wherein the method further comprises f) comparing the degree of inhibition by said second agent with said second cells of a first region of an organ with the degree of inhibition by said second agent with second cells of a second region of an organ.

25. The method of claim 1 , wherein said lamina propria-derived cell is viable after culture for 2 weeks in said micro fluidic device.

26. The method of claim 1 , wherein said parenchymal cell type expresses a higher level of parenchymal cell marker in the presence of said lamina propria-derived cell than in the absence of said of said lamina propria-derived cell.

Assignees

• Emulate Inc

Inventors

• Kerns S Jordan
• Barrile Riccardo
• Hamilton Geraldine
• Karalis Catherine
• Levner Daniel
• Lucchesi Carolina
• Varone Antonio
• Villenave Remi

Classifications

• C12M23/16 Primary

  Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093) · CPC title

• C12M29/04

  Filters; Permeable or porous membranes or plates, e.g. dialysis · CPC title

• C12M35/08

  Chemical, biochemical or biological means, e.g. plasma jet, co-culture · CPC title

• C12N5/0075

  using microcarriers · CPC title

• G01N33/5044

  involving specific cell types · CPC title